Hyperinsulinism-hyperammonemia syndrome
Hyperinsulinism-hyperammonemia syndrome (HI/HA syndrome) is a rare genetic disorder characterized by the combination of hyperinsulinism and elevated levels of ammonia in the blood. This condition is typically diagnosed in infancy or early childhood and can lead to severe hypoglycemia and neurological complications if not properly managed.
Etiology[edit | edit source]
HI/HA syndrome is caused by mutations in the GLUD1 gene, which encodes the enzyme glutamate dehydrogenase. This enzyme plays a crucial role in the regulation of insulin secretion and ammonia metabolism. Mutations in the GLUD1 gene lead to an overactive enzyme, resulting in excessive insulin release and elevated ammonia levels.
Clinical Features[edit | edit source]
The primary clinical features of HI/HA syndrome include:
- Persistent hypoglycemia due to excessive insulin secretion
- Elevated blood ammonia levels (hyperammonemia)
- Seizures
- Developmental delay
- Poor feeding and growth
Diagnosis[edit | edit source]
Diagnosis of HI/HA syndrome involves a combination of clinical evaluation, laboratory tests, and genetic testing. Key diagnostic criteria include:
- Persistent hypoglycemia with inappropriately high insulin levels
- Elevated plasma ammonia levels
- Identification of mutations in the GLUD1 gene through genetic testing
Management[edit | edit source]
Management of HI/HA syndrome focuses on controlling hypoglycemia and hyperammonemia. Treatment strategies include:
- Frequent feeding or continuous enteral feeding to prevent hypoglycemia
- Administration of medications such as diazoxide to reduce insulin secretion
- Use of ammonia scavengers to lower blood ammonia levels
- Dietary modifications to manage protein intake
Prognosis[edit | edit source]
The prognosis for individuals with HI/HA syndrome varies depending on the severity of the condition and the effectiveness of treatment. Early diagnosis and appropriate management are crucial for preventing severe hypoglycemia and minimizing neurological complications.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD